text size: T | T
Back to Snapshot
Company Description

Contact Info

4025 Sorrento Valley Boulevard

San Diego, CA 92121

United States

Phone: 858-678-0800

Fax: 858-678-0900

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies. The company has developed three drug candidates, advancing each of them into clinical trials, and built evidence to support its approach of targeting bioactive lipids to treat a range of diseases. Lpathomab Lpathomab is a humanized monoclonal antibody (mAb) against lysophosphatidic acid (LPA), a bioactive lipid that has been characterized in scientific literature as playing a key role in nerve injury and neuropathic pain. The company’s preclinical studies showed strong in vivo results with Lpathomab in various pain models, which suggest that LPA might be an attractive target across various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy. In 2016, the company completed the dosing of all subjects in its Phase 1a clinical trial of Lpathomab. iSONEP iSONEP is the ocular formulation of sonepcizumab, a mAb against sphingosine-1-phosphate. Sphingomab is the original mouse version of this monoclonal antibody. iSONEP is administered by intravitreal (inside the eye) injection, and has demonstrated various mechanisms of action in ocular models of disease, including anti-angiogenesis, anti-inflammatory, anti-fibrotic and anti-vascular permeability. ASONEP ASONEP is the systemic formulation of sonepcizumab. In 2015, the company announced that its Phase 2a clinical trial of ASONEP did not meet the primary endpoint of statistically significant progression-free survival. ASONEP is the systemic formulation of sonepcizumab. The ASONEP study follow-up period concluded during the third quarter of 2015. The company is exploring other indications where ASONEP might have more success. Collaboration Agreement In 2005, the company entered into a collaboration agreement (the ‘AERES Agreement’) with AERES Biomedical Limited (AERES) to ‘humanize’ the company’s Sphingomab monoclonal antibody. Patents and Proprietary Rights The company’s patent portfolio includes 70 issued patents, including 35 foreign patents, and 79 pending patents, including 61 foreign patent applications. The company’s issued patents begin to expire in 2017. Trademarks iSONEP, ASONEP Lpathomab, ImmuneY2 and the company’s logo are its trademarks. Regulations The company is required to submit the results of preclinical tests, together with manufacturing information and analytical data, to the FDA as part of an Investigational New Drug, which must become effective before it begins human clinical trials.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.1x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact LPATH INC-CLASS A, please visit www.lpath.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.